Podolskaya D V, Shapina M V, Khalif I L
Eksp Klin Gastroenterol. 2016(8):4-8.
Colorectal cancer (CRC) is an actual problem today And it occurs 6 times more frequently in patients with inflammatory bowel diseases (IBD) than in healthy population. CRC in IBD patients is more aggressive and needs total colectomy, which leads to permanent disability That is why canceroprevention is one of the key goals of IBD treatment. The aim of this review is to overview actual pathogenesis pathways of CRC in IBD and methods of chemoprevention. In this review we describe risk factors of CRC, which can be summarized as aggressive disease and chronic inflammation and are based on pathogenesis of CRC. That is the reason why methods of chemoprevention needs to influence on inflammation and other pathogenesis pathways. The role of such classes of medication as non-steroidal anti-inflammatory drugs, 5-aminosalicylic acid, immunomodulators, ursodeoxycholic acid in canceroprevention in RD patients are described in this review.
结直肠癌（CRC）是当今一个切实存在的问题。它在炎症性肠病（IBD）患者中的发生率比在健康人群中高6倍。IBD患者中的CRC更具侵袭性，需要进行全结肠切除术，这会导致永久性残疾。这就是为什么癌症预防是IBD治疗的关键目标之一。本综述的目的是概述IBD中CRC的实际发病机制途径和化学预防方法。在本综述中，我们描述了CRC的危险因素，这些因素可概括为侵袭性疾病和慢性炎症，并且基于CRC的发病机制。这就是为什么化学预防方法需要影响炎症和其他发病机制途径。本综述描述了非甾体类抗炎药、5-氨基水杨酸、免疫调节剂、熊去氧胆酸等药物类别在IBD患者癌症预防中的作用。
